{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:48:52Z","timestamp":1767149332172,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.revmed.2023.11.010","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000}}],"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021716","name":"Universit\u00e9 Paris Cit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.revmed.2023.11.010","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T18:40:32Z","timestamp":1701801632000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WITHDRAWN: Autogreffe de cellules souches p\u00e9riph\u00e9riques dans la scl\u00e9rodermie syst\u00e9mique\u00a0: un progr\u00e8s important, mais il faut temp\u00e9rer notre enthousiasme !"],"prefix":"10.1016","author":[{"given":"L.","family":"Mouthon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2023.11.010_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2023.11.010_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.010_bib0015","doi-asserted-by":"crossref","first-page":"104088","DOI":"10.1016\/j.lpm.2021.104088","article-title":"Treatment of systemic sclerosis","volume":"50","author":"Thoreau","year":"2021","journal-title":"Presse Med"},{"issue":"9790","key":"10.1016\/j.revmed.2023.11.010_bib0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2\u00a0trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.revmed.2023.11.010_bib0025","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.010_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2023.11.010_bib0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.revmed.2023.11.010_bib0040","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"25","key":"10.1016\/j.revmed.2023.11.010_bib0045","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.010_bib0050","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u00a0years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.revmed.2023.11.010_bib0055","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.revmed.2023.11.010_bib0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","article-title":"French recommendations for the management of systemic sclerosis","volume":"16","author":"Hachulla","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"26","key":"10.1016\/j.revmed.2023.11.010_bib0065","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.010_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.revmed.2023.11.010_bib0075","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/annrheumdis-2020-217033","article-title":"Machine learning predicts stem cell transplant response in severe scleroderma","volume":"79","author":"Franks","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.010_bib0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/2397198320971967","article-title":"Hematopoietic stem cell transplantation in systemic sclerosis: yes!! BUT","volume":"6","author":"Al Odhaibi","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"issue":"9872","key":"10.1016\/j.revmed.2023.11.010_bib0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.revmed.2023.11.010_bib0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12\u00a0years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.revmed.2023.11.010_bib0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.revmed.2023.11.010_bib0100","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","article-title":"Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party","volume":"118","author":"Daikeler","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2023.11.010_bib0105","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood-2006-01-0176","article-title":"Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD","volume":"108","author":"Rov\u00f3","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.revmed.2023.11.010_bib0110","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00296-016-3531-2","article-title":"Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation","volume":"36","author":"Massenkeil","year":"2016","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.010_bib0115","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u00a0years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.revmed.2023.11.010_bib0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1704656","article-title":"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis","volume":"34","author":"Saccardi","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.revmed.2023.11.010_bib0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50\u00a0patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1016\/j.revmed.2023.11.010","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000}}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866323012973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:49:24Z","timestamp":1759319364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866323012973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"alternative-id":["S0248866323012973"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.010","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Autogreffe de cellules souches p\u00e9riph\u00e9riques dans la scl\u00e9rodermie syst\u00e9mique\u00a0: un progr\u00e8s important, mais il faut temp\u00e9rer notre enthousiasme !","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2023.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}